Nanologica receives order for NLAB Saga valued to approximately SEK 2 Million

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million.

The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production.

“In China, we see a very strong activity in the GLP-1 analogue segment as a result of the patent for semaglutide expiring in 2026. The demand for high-quality silica for purification of peptides such as semaglutide has increased significantly in China, just as in the rest of the world, and this order shows that we can take on the Chinese market”, CEO Andreas Bhagwani comments.

“As we announced earlier this week, our large-scale silica production facility is now delivering significantly larger volumes than before. How much more that will land as sales in the second quarter remains to be seen, but with an increasing stock of finished goods, we are able to deliver faster on this and future orders, which means that we can increase our sales efforts ”, CEO Andreas Bhagwani continues.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-06-20 10:24 CEST.

Links